RPL10A Antibody

What is RPL10A and why is it important in cellular function?

RPL10A (ribosomal protein L10a) is a 25 kDa component of the 60S ribosomal subunit that plays critical roles in protein synthesis . Beyond its canonical role in translation, recent research has revealed specialized functions in stem cell differentiation and development . Notably, RPL10A has been implicated in mesoderm development through regulation of Wnt signaling pathways, with loss-of-function alleles in mice causing striking mesodermal phenotypes including posterior trunk truncations . Additionally, RPL10A has been found to influence pancreatic cancer cell stemness through post-translational modifications .

Confirming antibody specificity is crucial for experimental validity. A comprehensive approach includes:

• Validation using multiple cell/tissue types: Test antibody in several known RPL10A-expressing samples (e.g., HeLa, HepG2, brain, and liver tissues) .

• Molecular weight verification: Confirm detection of a band at approximately 25 kDa by Western blot, which corresponds to the calculated molecular weight of RPL10A .

• Subcellular localization: Use immunofluorescence to verify characteristic nucleolar, cytosolic, and endoplasmic reticulum localization patterns of RPL10A .

• Controls: Include positive controls (tissues/cells known to express RPL10A) and negative controls (secondary antibody only) in each experiment .

• Cross-reactivity assessment: If working with non-human samples, verify cross-reactivity with your species of interest using validated antibodies that specify reactivity with your target species .

What are the optimal dilutions and conditions for using RPL10A antibodies in Western blot applications?

Western blotting with RPL10A antibodies requires careful optimization of several parameters:

Methodological guidance for optimal results:

• Use 25μg of protein lysate per lane

• Block in 3% nonfat dry milk in TBST

• For detection, standard ECL systems are sufficient given RPL10A's abundance

• Secondary antibody dilution typically ranges from 1:5000 to 1:10000

• Include appropriate molecular weight markers to confirm 25 kDa band size

How should I optimize immunohistochemistry protocols for RPL10A detection in tissue samples?

Optimizing immunohistochemistry for RPL10A requires attention to several critical factors:

Methodological recommendations:

• Tissue preparation: Use freshly fixed tissues and proper paraffin embedding to preserve antigenic sites

• Antigen retrieval: High-pressure antigen retrieval with citrate buffer (pH 6.0) is most commonly reported for successful RPL10A detection

• Background reduction: Include thorough blocking steps and proper controls

• Detection systems: For tissues with lower expression, consider amplification systems like ABC or polymer-based detection

• Counterstaining: Use hematoxylin for nuclear definition, which helps evaluate the predominantly cytoplasmic and nucleolar RPL10A staining

What are the best practices for immunofluorescence experiments using RPL10A antibodies?

Successful immunofluorescence for RPL10A detection requires specific optimization:

Methodological best practices:

• Fixation: Use 4% paraformaldehyde for preserving RPL10A localization in cellular compartments

• Permeabilization: Optimize detergent concentration (typically 0.1-0.5% Triton X-100) to access intracellular RPL10A without disrupting structures

• Blocking: Extended blocking (1-2 hours) with serum-based blockers to minimize background

• Antibody incubation: Overnight incubation at 4°C with primary antibody often yields better results than short incubations

• Visualization: Use confocal microscopy to properly resolve the nucleolar, cytoplasmic, and endoplasmic reticulum localization of RPL10A

• Co-localization studies: Consider dual staining with nucleolar markers for enhanced interpretation of localization patterns

How can RPL10A antibodies be utilized in ribosome profiling and specialized ribosome studies?

RPL10A antibodies are valuable tools for investigating ribosome heterogeneity and specialized translation:

Methodological approaches:

• Translating Ribosome Affinity Purification (TRAP): RPL10A antibodies can be used to immunoprecipitate RPL10A-containing ribosomes to study specialized translational regulation in specific cell types .

• Ribosome profiling applications: RPL10A antibodies facilitate identification of transcripts specifically associated with RPL10A-containing ribosomes. Research has shown that RPL10A regulates translation of mesoderm regulators, including Wnt pathway mRNAs, which are enriched on RPL10A/uL1-containing ribosomes .

• Polysome fractionation: RPL10A antibodies can be used to analyze polysome fractions to determine if RPL10A incorporation into ribosomes varies across different translational states.

• Proximity labeling approaches: RPL10A antibodies can be combined with techniques like BioID or APEX to identify proteins in spatial proximity to RPL10A within the ribosomal complex.

Recent findings demonstrate that ribosome composition changes during stem cell differentiation, with RPL10A playing a critical role in regulating the production of mesoderm lineage through specialized translation of key signaling networks .

What are the appropriate methods for studying post-translational modifications of RPL10A?

RPL10A undergoes several post-translational modifications that affect its function:

Methodological guidelines:

• Ufmylation detection: To study RPL10A ufmylation (a ubiquitin-like modification):

  • Co-immunoprecipitation with anti-RPL10 and anti-UFM1 antibodies

  • Western blot analysis with anti-UFM1 detection to identify modified RPL10A

  • Validated antibodies for this approach include anti-UFM1 (Abcam, #ab109305) used at appropriate dilutions

• Phosphorylation studies:

  • Phospho-specific antibodies or phospho-enrichment combined with mass spectrometry

  • Lambda phosphatase treatment as a control to confirm phosphorylation status

• Ubiquitination analysis:

  • Immunoprecipitation under denaturing conditions to preserve ubiquitin modifications

  • Detection with anti-ubiquitin antibodies

  • MG132 proteasome inhibitor treatment to enhance detection of ubiquitinated forms

Recent research has shown that ufmylation of RPL10 plays an important role in enhancing the stemness of pancreatic cancer cells, suggesting post-translational modifications of ribosomal proteins contribute to cancer development .

How can I investigate RPL10A's role in development and stem cell differentiation?

Based on recent discoveries about RPL10A's developmental roles:

Methodological approaches:

• CRISPR/Cas9-mediated RPL10A modification:

  • Generation of null alleles through deletion of coding sequence

  • Introduction of N-terminal modifications to affect interactions with target mRNAs or protein partners

  • Use of conditional knockout systems for tissue-specific or temporal control of RPL10A expression

• Stem cell differentiation assays:

  • In vitro differentiation of stem cells (ESCs) toward mesodermal lineages

  • Analysis of RPL10A levels during differentiation

  • Assessment of Wnt signaling pathway components, as RPL10A regulates both canonical and non-canonical Wnt signaling

• Compensatory mechanisms analysis:

  • Heterozygous models show no phenotypes due to complete compensation from the wild-type allele

  • Careful quantification of mRNA and protein levels required to verify compensation mechanisms

• Embryonic phenotyping:

  • Complete loss of RPL10A is early embryonic lethal (before E9.5)

  • Extended protein variants may survive until perinatal stages

Key finding: Rpl10a loss-of-function in mice causes striking early mesodermal phenotypes, including posterior trunk truncations and inhibits paraxial mesoderm production in culture, revealing RPL10A's essential role in development .

How can I resolve common issues in Western blotting with RPL10A antibodies?

Common issues and solutions for RPL10A Western blotting:

Special considerations for RPL10A:

• Be aware that RPL10A shares 98% amino acid sequence similarity with RPL10L, which can cause cross-reactivity in some samples

• For differentiating between RPL10A and related proteins, consider using monoclonal antibodies for higher specificity

• Validate results using multiple antibody clones when possible

What are the key considerations for optimizing immunoprecipitation experiments with RPL10A antibodies?

Optimizing immunoprecipitation with RPL10A antibodies requires attention to several parameters:

Methodological recommendations:

• Antibody selection and amount:

  • For Proteintech antibody 16681-1-AP: Use 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

  • For co-immunoprecipitation: Consider antibodies validated specifically for IP applications

• Lysis conditions:

  • Use gentle lysis buffers (e.g., RIPA buffer with protease inhibitors) to preserve protein-protein interactions

  • For studying RPL10A's interactions with ribosomal components, avoid high salt or detergent concentrations that may disrupt ribosome assembly

  • Include RNase inhibitors if RNA-dependent interactions are of interest

• Incubation parameters:

  • Optimal conditions: 16 hours at 4°C for antibody-lysate mixture, followed by 1 hour with agarose beads at room temperature

  • Five thorough washes with lysis buffer to reduce non-specific binding

• Elution and detection:

  • Boil precipitates with loading buffer for 5 minutes before SDS-PAGE and Western blotting

  • Use appropriate controls including IgG-only controls and input samples

• Special considerations for studying ribosomal complexes:

  • Include magnesium in buffers to preserve intact ribosomal complexes

  • Consider cross-linking approaches for stabilizing transient interactions

How should I approach conflicting results when studying RPL10A in different experimental systems?

When facing contradictory findings in RPL10A research:

Methodological approach to reconciling contradictions:

• Antibody validation across systems:

  • Verify antibody specificity in each experimental system

  • Consider using multiple antibodies recognizing different epitopes

  • Include both polyclonal (e.g., Proteintech 16681-1-AP) and monoclonal (e.g., ABClonal A20944) antibodies

• Expression level variations:

  • RPL10A expression varies across tissues and developmental stages

  • Quantify absolute expression levels using qPCR and calibrated Western blots

  • Consider tissue-specific post-translational modifications that might affect antibody detection

• Functional compensation mechanisms:

  • In heterozygous models, complete compensation from wild-type alleles can occur

  • Quantify both mRNA and protein levels to verify compensation mechanisms

  • Consider functional redundancy with related ribosomal proteins

• Technical considerations for contradicting results:

  • Different antibody dilutions can significantly impact results (e.g., 1:10-1:100 for IF vs. 1:1000-1:6000 for WB)

  • Antigen retrieval methods affect epitope accessibility (citrate buffer pH 6.0 vs. TE buffer pH 9.0)

  • Primary and secondary antibody combinations may introduce variability

• Biological context:

  • RPL10A functions may differ between stem cells and differentiated tissues

  • Disease states (e.g., cancer) can alter RPL10A function through post-translational modifications

  • Developmental stage significantly impacts RPL10A's role and experimental outcomes

How can RPL10A antibodies be utilized in cancer research?

Recent findings highlight RPL10A's relevance in cancer biology:

Methodological approaches:

• Analysis of stemness markers in cancer:

  • RPL10A ufmylation enhances stemness of pancreatic cancer cells

  • Co-analysis with stemness markers (KLF4, Nanog, Oct4, Sox2) using validated antibodies

  • Correlation of RPL10A modifications with cancer progression markers

• Investigating post-translational modifications:

  • Use of specific antibodies against modifications (e.g., anti-UFM1, Abcam #ab109305)

  • Analysis of modification enzymes (UFL1, UFSP2) that regulate RPL10A function

  • Comparison of modification patterns between normal and cancerous tissues

• Therapeutic targeting approaches:

  • Screening for compounds that selectively disrupt modified RPL10A function

  • Analysis of cancer cell sensitivity to disruption of RPL10A-dependent translation

  • Correlation with patient outcomes and treatment responses

This emerging area requires careful experimental design and appropriate controls to distinguish RPL10A's canonical ribosomal function from its specialized roles in cancer stemness .

What are the considerations for studying RPL10A in the context of ribosome heterogeneity?

Ribosome heterogeneity is an emerging field with significant methodological considerations:

Methodological guidance:

• Cell type-specific ribosome analysis:

  • TRAP (Translating Ribosome Affinity Purification) using RPL10A antibodies

  • Single-cell approaches to detect variation in ribosome composition

  • Comparison across differentiation states and developmental timepoints

• Specialized translation detection:

  • Ribosome profiling to identify mRNAs preferentially translated by RPL10A-containing ribosomes

  • Focus on mesoderm regulators and Wnt pathway mRNAs, which are enriched on RPL10A/uL1-containing ribosomes

  • Comparison of translation efficiency between different ribosome populations

• Structural analysis:

  • Cryo-EM approaches to determine how RPL10A incorporation affects ribosome structure

  • Investigation of how structural changes influence mRNA selection and translation dynamics

  • Combination with functional assays to correlate structural differences with biological outcomes

• Developmental context:

  • Temporal analysis during embryonic development using stage-appropriate samples

  • Correlation with developmental milestones, particularly in mesoderm formation

  • Assessment of RPL10A's influence on both canonical and non-canonical Wnt signaling

Recent research demonstrates unexpected ribosome composition modularity that controls differentiation and development through the specialized translation of key signaling networks, with RPL10A playing a crucial role in this process .